Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10891097 | 0.83 | RECQL (0.50) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL32667239 | 0.83 | KDM4E (0.58) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL486699 | 0.82 | ALDH1A1 (0.66) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL2112989 | 0.81 | TDP1 (0.49) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL4590541 | 0.81 | ALDH1A1 (0.64) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL27814718 | 0.79 | ALDH1A1 (0.62) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL14367258 | 0.79 | KMT2A (0.47) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL22079383 | 0.79 | SMN1; SMN2 (0.49) | ALDH1A1LMNAKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL14367255 | 0.79 | KDM4E (0.46) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL12079342 | 0.78 | ALDH1A1 (0.60) | ALDH1A1LMNAKMT2ARECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | ALDH1A1 456/4885LMNA 685/4885KMT2A 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.